AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31848857 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHWs) intervention for diabetes prevention
Number of subjects: 54
Study 31566031 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable EEG headband for guided meditation
Number of subjects: 30
Study 31566031 — intervention group
Group type: COMPARATOR
Intervention: CD-based stress-reduction education
Number of subjects: 30
Study 31566031 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 30
Study 28419095 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV (Rotarix) vaccination program
Number of subjects: 142
Study 28419095 — intervention group
Group type: COMPARATOR
Intervention: Standard infant vaccines without HRV
Number of subjects: 142
Study 28419095 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV vaccination program
Number of subjects: 142
Study 24265118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 57
Study 24265118 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 57
Study 24011514 — intervention group
Group type: EXPERIMENTAL
Intervention: NCB-02 (curcumin) enema plus oral 5-ASA
Number of subjects: 45
Study 24011514 — intervention group
Group type: COMPARATOR
Intervention: Placebo enema plus oral 5-ASA
Number of subjects: 45
Study 22529754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral methods for controlled eating
Number of subjects: 430
Study 22529754 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition education
Number of subjects: 430
Study 19183561 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic cues (color words: 'red', 'green', 'blue', 'yellow' and location words: 'up', 'down', 'left', 'right')
Number of subjects: 0
Study 19183561 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent trials
Number of subjects: 0
Study 19183561 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent trials
Number of subjects: 0
Study 17305732 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrax
Number of subjects: 60
Study 17305732 — intervention group
Group type: COMPARATOR
Intervention: Celoftal
Number of subjects: 60
Study 17305732 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 60
Study 15105390 — intervention group
Group type: EXPERIMENTAL
Intervention: eSET (elective single embryo transfer) with ICSI (Intracytoplasmic Sperm Injection)
Number of subjects: 468
Study 15105390 — intervention group
Group type: EXPERIMENTAL
Intervention: eSET (elective single embryo transfer)
Number of subjects: 468
Study 15105390 — intervention group
Group type: COMPARATOR
Intervention: ICSI (Intracytoplasmic Sperm Injection)
Number of subjects: 468
Study 15105390 — intervention group
Group type: COMPARATOR
Intervention: IVF (In Vitro Fertilization)
Number of subjects: 468
Study 15105390 — intervention group
Group type: COMPARATOR
Intervention: IVF cycles
Number of subjects: 468
Study 11205180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-screening assay
Number of subjects: 0
Study 11205180 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 0
Study 9602258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU rhEPO daily s.c.
Number of subjects: 227
Study 7981574 — intervention group
Group type: EXPERIMENTAL
Intervention: GH response to GHRH in Alzheimer's disease (n = 28)
Number of subjects: 86
Study 7981574 — intervention group
Group type: EXPERIMENTAL
Intervention: GH response to GHRH in parkinsonism with dementia (n = 10)
Number of subjects: 86
Study 7981574 — intervention group
Group type: EXPERIMENTAL
Intervention: GH response to GHRH in progressive supranuclear palsy with dementia (n = 10)
Number of subjects: 86
Study 7981574 — intervention group
Group type: EXPERIMENTAL
Intervention: GH response to GHRH in dementia of vascular origin (n = 28)
Number of subjects: 86
Study 7981574 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH response to TRH in Alzheimer's disease (n = 28)
Number of subjects: 86
Study 7981574 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH response to TRH in parkinsonism with dementia (n = 10)
Number of subjects: 86
Study 7981574 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH response to TRH in progressive supranuclear palsy with dementia (n = 10)
Number of subjects: 86
Study 7981574 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH response to TRH in dementia of vascular origin (n = 28)
Number of subjects: 86
Study 31501293 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal ultrafiltration (PuF) with 1 overnight exchange using Icodextrin dialysate
Number of subjects: 10
Study 31501293 — intervention group
Group type: COMPARATOR
Intervention: Continuation of conventional HF treatment
Number of subjects: 10
Study 27915068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound therapy (1W/cm2, pulsed: 1:5)
Number of subjects: 12
Study 27915068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intensity: zero)
Number of subjects: 12
Study 26779673 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic facial composite construction by participant-witnesses
Number of subjects: 0
Study 26779673 — intervention group
Group type: COMPARATOR
Intervention: Control group (no composite construction)
Number of subjects: 0
Study 25173550 — intervention group
Group type: EXPERIMENTAL
Intervention: SB predilation
Number of subjects: 372
Study 25173550 — intervention group
Group type: COMPARATOR
Intervention: No predilation
Number of subjects: 372
Study 23176246 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plane of nutrition (HPN; 0.30 Mcal intake energy/kg of metabolic body weight using a 28% protein‐20% fat milk replacer)
Number of subjects: 20
Study 23176246 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plane of nutrition (HPN)
Number of subjects: 20
Study 23176246 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutrition (CN; 0.13 Mcal intake energy/kg of metabolic body weight using a 20% protein‐20% fat milk replacer)
Number of subjects: 20
Study 23176246 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutrition (CN)
Number of subjects: 20
Study 19464709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1200 mg daily for 12 months
Number of subjects: 34
Study 19464709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF)
Number of subjects: 34
Study 16409425 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weekly regimen of gemcitabine (1000 mg/qm, days 1 and 8) and paclitaxel (175 mg/qm, day 1)
Number of subjects: 30
Study 16409425 — intervention group
Group type: COMPARATOR
Intervention: 2-weekly regimen of gemcitabine (1250 mg/qm, day 1) and paclitaxel (120 mg/qm, day 2)
Number of subjects: 30
Study 15281431 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma-1b 200 microg sc
Number of subjects: 10
Study 15281431 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg qd plus prednisone 10 mg qd
Number of subjects: 10
Study 15281431 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 10
Study 11284782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg b.d.
Number of subjects: 320
Study 11284782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1.0 mg b.d.
Number of subjects: 320
Study 11284782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 2.0 mg b.d.
Number of subjects: 320
Study 11284782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 9253567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.3 microgram kg‐1 i.v.) added in group 2
Number of subjects: 18
Study 9253567 — intervention group
Group type: COMPARATOR
Intervention: Desflurane administration in both groups
Number of subjects: 18
Study 8432597 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhi Ty21a vaccine
Number of subjects: 634
Study 8432597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study 3567001 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms aerosol
Number of subjects: 0
Study 3567001 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 670 mg (high-dose)
Number of subjects: 0
Study 3567001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aerosol and infusion)
Number of subjects: 0
Study 29371859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking under the influence of alcohol
Number of subjects: 200
Study 29371859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking under the influence of marijuana
Number of subjects: 200
Study 29371859 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived pleasure from smoking cigarettes when drinking alcohol
Number of subjects: 200
Study 29371859 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived pleasure from smoking cigarettes when using marijuana
Number of subjects: 200
Study 29371859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers who used alcohol + marijuana
Number of subjects: 200
Study 27633173 — intervention group
Group type: EXPERIMENTAL
Intervention: LP0132-fermented juice
Number of subjects: 33
Study 27633173 — intervention group
Group type: COMPARATOR
Intervention: Unfermented citrus juice (placebo)
Number of subjects: 33
Study 24763840 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 μg) plus 9 mL of saline
Number of subjects: 75
Study 24763840 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (10 mL of 2% lignocaine with adrenaline 1:200,000)
Number of subjects: 75
Study 24763840 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (20 mL of 0.75% ropivacaine)
Number of subjects: 75
Study 22155931 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxic breathing simulating 4100 m altitude
Number of subjects: 10
Study 22155931 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to normoxia
Number of subjects: 10
Study 19916742 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and cetuximab
Number of subjects: 0
Study 18281266 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU s.c. of IFNalpha2a three times a week for 2 years (Arm A)
Number of subjects: 444
Study 18281266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with 3 MU s.c. of IFNalpha2a plus DTIC 850 mg/m(2) every 4‐8 weeks for 2 years (Arm B)
Number of subjects: 444
Study 18281266 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (Arm C)
Number of subjects: 444
Study 15979016 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) treatment
Number of subjects: 29
Study 12437432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cymetra
Number of subjects: 44
Study 12437432 — intervention group
Group type: COMPARATOR
Intervention: Zyplast
Number of subjects: 44
Study 10515401 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 26
Study 10515401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7674318 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly predictive genetic test
Number of subjects: 0
Study 7674318 — intervention group
Group type: EXPERIMENTAL
Intervention: New trials including persons at very high risk of developing cancer
Number of subjects: 0
Study 7674318 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial
Number of subjects: 0
Study 1651856 — intervention group
Group type: EXPERIMENTAL
Intervention: pipecuronium 45 micrograms kg‐1
Number of subjects: 90
Study 1651856 — intervention group
Group type: COMPARATOR
Intervention: pancuronium 60 micrograms kg‐1
Number of subjects: 90
Study 1651856 — intervention group
Group type: EXPERIMENTAL
Intervention: pipecuronium 70 micrograms kg‐1
Number of subjects: 90
Study 1651856 — intervention group
Group type: EXPERIMENTAL
Intervention: pipecuronium (both doses)
Number of subjects: 90
Study 7451732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 40
Study 7451732 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking analgesia
Number of subjects: 40
Study 7451732 — intervention group
Group type: COMPARATOR
Intervention: No analgesia (control)
Number of subjects: 40
Study 30977520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Number of subjects: 2566
Study 30977520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2566
Study 29519686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangzhiqing tablet (TZQ)
Number of subjects: 0
Study 29519686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuciferine and paeoniflorin
Number of subjects: 0
Study 29519686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27258301 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISE (5-6 meals/day at 2.0 g/kg BW/day)
Number of subjects: 30
Study 24191977 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological awareness intervention (8-week program, 4 times a week, 25 min per session)
Number of subjects: 75
Study 24191977 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological awareness intervention
Number of subjects: 75
Study 22237854 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg aripiprazole
Number of subjects: 11
Study 19295332 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HIV)
Number of subjects: 368
Study 19295332 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using the EQ-5D
Number of subjects: 368
Study 19295332 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using the Health Utilities Index Mark 3 (HUI3)
Number of subjects: 368
Study 19295332 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using the EQ-5D visual analog scale (EQ-5D VAS)
Number of subjects: 368
Study 19295332 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using standard gamble (SG) technique
Number of subjects: 368
Study 19295332 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using time trade-off (TTO) technique
Number of subjects: 368
Study 17576969 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine with ketamine 1 mg ml(‐1)
Number of subjects: 50
Study 17576969 — intervention group
Group type: COMPARATOR
Intervention: Morphine 1 mg ml(‐1)
Number of subjects: 50
Study 15323577 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifracture therapy (specifics not provided)
Number of subjects: 0
Study 15323577 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multiple vertebral fractures
Number of subjects: 0
Study 15323577 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-QOL instruments
Number of subjects: 0
Study 11713072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral lidocaine (0.5 ml preservative-free 2%)
Number of subjects: 15
Study 11713072 — intervention group
Group type: COMPARATOR
Intervention: Intracameral saline (0.5 ml sterile saline)
Number of subjects: 15
Study 9228128 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 219
Study 9228128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 7955553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 200 mg/day over 5 days
Number of subjects: 8
Study 7955553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol cessation
Number of subjects: 8
Study 7955553 — intervention group
Group type: COMPARATOR
Intervention: Cortisol treatment
Number of subjects: 8
Study 2885505 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Sb/kg per day for twenty days
Number of subjects: 40
Study 2885505 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Sb/kg per day for twenty days
Number of subjects: 40
Study 31796259 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing ambient air adjacent to a steel plant
Number of subjects: 59
Study 31796259 — intervention group
Group type: COMPARATOR
Intervention: Breathing ambient air 5 km away at a college campus site
Number of subjects: 59
Study 30968798 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training program (CCT program)
Number of subjects: 69
Study 30968798 — intervention group
Group type: COMPARATOR
Intervention: Active control games program
Number of subjects: 69
Study 29274030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 463
Study 29274030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 463
Study 29274030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 27457369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT, 0.3 W, 40 s, 4 J/cm²)
Number of subjects: 15
Study 27457369 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative recommendation (ice application)
Number of subjects: 15
Study 24862638 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 HLA‐mismatched umbilical cord blood (UCB) units
Number of subjects: 2
Study 24862638 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow from HLA‐haploidentical relatives
Number of subjects: 2
Study 22000279 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg/day
Number of subjects: 610
Study 22000279 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg/day
Number of subjects: 610
Study 22000279 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 10 mg/day
Number of subjects: 610
Study 22000279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 22000279 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline (all doses)
Number of subjects: 610
Study 21319605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandwidth knowledge of results (KR) at 5%
Number of subjects: 0
Study 21319605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandwidth knowledge of results (KR) at 10%
Number of subjects: 0
Study 21319605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandwidth knowledge of results (KR) at 15%
Number of subjects: 0
Study 21319605 — intervention group
Group type: COMPARATOR
Intervention: Control group (0% bandwidth KR)
Number of subjects: 0
Study 18685349 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and parenteral opioids
Number of subjects: 0
Study 18685349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose regular opioids (especially sustained-release preparations)
Number of subjects: 0
Study 18685349 — intervention group
Group type: EXPERIMENTAL
Intervention: Other medications (benzodiazepines, nebulised frusemide, selective serotonin reuptake inhibitors)
Number of subjects: 0
Study 16032487 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 103
Study 16032487 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 103
Study 11844656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestin (1.2 g twice daily for 8 weeks)
Number of subjects: 14
Study 11844656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestin (1.2 g twice daily for 2 weeks)
Number of subjects: 14
Study 11844656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11844656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestin
Number of subjects: 14
Study 10486647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (without LVH)
Number of subjects: 73
Study 10486647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (with LVH)
Number of subjects: 73
Study 10486647 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 73
Study 7480980 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg rhDNase twice daily for 6 months followed by a 2-week wash-out period, then rhDNase once daily for 18 months
Number of subjects: 52
Study 1673816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 0.07 mg kg‐1
Number of subjects: 30
Study 1673816 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine 0.03 mg kg‐1
Number of subjects: 30
Study 7125090 — intervention group
Group type: EXPERIMENTAL
Intervention: Soludactone: 300 mg daily for one week, followed by aldactone orally
Number of subjects: 20
Study 7125090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7125090 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations
Number of subjects: 20
Study 31765988 — intervention group
Group type: EXPERIMENTAL
Intervention: Xelox + AZD8931 (20 mg bd with 4/3 schedule)
Number of subjects: 30
Study 31765988 — intervention group
Group type: COMPARATOR
Intervention: Xelox only
Number of subjects: 30
Study 31765988 — intervention group
Group type: EXPERIMENTAL
Intervention: Xelox + AZD8931
Number of subjects: 30
Study 31272421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component implementation support intervention to embed the seven school PA practices of the PA4E1 program.
Number of subjects: 76
Study 31272421 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control arm
Number of subjects: 76
Study 31272421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component implementation support intervention
Number of subjects: 76
Study 28193301 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone or aripiprazole
Number of subjects: 29
Study 28193301 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 29
Study 25999337 — intervention group
Group type: EXPERIMENTAL
Intervention: Case formulation
Number of subjects: 0
Study 25999337 — intervention group
Group type: EXPERIMENTAL
Intervention: Homework tasks
Number of subjects: 0
Study 25999337 — intervention group
Group type: EXPERIMENTAL
Intervention: Active change strategies
Number of subjects: 0
Study 24120017 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based tool
Number of subjects: 102
Study 24120017 — intervention group
Group type: COMPARATOR
Intervention: Manual algorithm
Number of subjects: 102
Study 22906319 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded-exercise therapy (GET)
Number of subjects: 163
Study 22906319 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (COUN)
Number of subjects: 163
Study 22906319 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus a self-help booklet (BUC)
Number of subjects: 163
Study 19321313 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem enhancement program for individuals with severe mental illness (case-management care)
Number of subjects: 54